obesity overweight weight loss weigh
Biotech

Lilly triple-G drug hits 22% weight loss, cardio impact unclear

Retatrutide hit the primary endpoints of a pair of phase 3 obesity trials, while failing to prove the drug reduces cardiovascular risk.
James Waldron Jul 23, 2026 9:06am
Panther Rare Pharmacy

De-risking rare disease launches: precision beats scale

Brought to you by PANTHERx® Rare Pharmacy
AAIC Roche

Roche drops lupus TCE, retains autoimmune cell therapy interest

Jul 23, 2026 4:51am
shutterstock2729915667png

Understanding Agentic AI in Clinical Development

Brought to you by Syneos Health
India India pharma Indian pharmaceutical industry rupee pills

How India can build on its budding innovative R&D moment: report

Jul 23, 2026 5:00am
water forest

Scancell heads to Nasdaq via reverse merger with Neuphoria

Jul 23, 2026 10:13am
More News

Fierce Biotech Layoff Tracker 2026: Clinuvel, Novartis, & more

Jul 23, 2026 9:00am

Australia's Clinuvel to shed up to 20% of workforce in US move

Jul 23, 2026 5:47am

NIH joins Trump’s $5B AI mission with biomedical research push

Jul 22, 2026 2:43pm

House passes bill directing FDA to update animal testing rules

Jul 22, 2026 10:55am